SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on December 27, 2002; DOI 10.1182/blood-2002-05-1376. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-05-1376v1 101/8/3319    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Storek, J. Articles by Maloney, D. G. Search for Related Content PubMed PubMed Citation Articles by Storek, J. Articles by Maloney, D. G. Related Collections Immunobiology Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 April 2003, Vol. 101, No. 8, pp. 3319-3324 TRANSPLANTATION Factors affecting antibody levels after allogeneic hematopoietic cell transplantation Jan Storek, Federico Viganego, Monja A. Dawson, M. M. P. Tineke Herremans, Michael Boeckh, Mary E. D. Flowers, Barry Storer, William I. Bensinger, Robert P. Witherspoon, and David G. Maloney From the Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA; University of Washington, Seattle, WA; and the National Institute of Public Health and Environment, Bilthoven, the Netherlands. To obtain insight into the mechanism(s) of posttransplantation humoral immunodeficiency, we evaluated factors affecting serum antibody levels against polio, tetanus, Haemophilus influenzae, and Streptococcus pneumoniae in 87 patients. Patients with hematologic malignancies were randomized to receive marrow versus blood stem cells, which contain approximately 10 times more lymphocytes than marrow. Blood stem cell recipients did not have higher antibody levels than marrow recipients. Recipient pretransplantation antibody levels were correlated with the posttransplantation levels, especially in the first 6 months after transplantation when the correlation coefficients typically exceeded 0.6. Donor pretransplantation antibody levels had less of a correlation with posttransplantation levels in the recipient. Patient or donor age, total body irradiation, and graft-versus-host disease or its treatment appeared to have no effect. In conclusion, antibody levels in the first year after transplantation are affected primarily by pretransplantation antibody levels in the recipient and, to a lesser degree, in the donor. These findings suggest that immunization of the recipient and the donor before transplantation may be more effective in improving antibody immunity after transplantation than manipulating graft-versus-host disease, changing conditioning, or increasing the number of lymphocytes in the graft. © 2003 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. H. T. Paraiso, T. Ghansah, A. Costello, R. W. Engelman, and W. G. Kerr Induced SHIP Deficiency Expands Myeloid Regulatory Cells and Abrogates Graft-versus-Host Disease J. Immunol., March 1, 2007; 178(5): 2893 - 2900. [Abstract] [Full Text] [PDF] D. N. Levasseur, T. M. Ryan, K. M. Pawlik, and T. M. Townes Correction of a mouse model of sickle cell disease: lentiviral/antisickling {beta}-globin gene transduction of unmobilized, purified hematopoietic stem cells Blood, December 15, 2003; 102(13): 4312 - 4319. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020